Emergent BioSolutions to Participate in First Quarter 2016 Investor Conferences

GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2016.

• 34th Annual J.P. Morgan Healthcare Conference San Francisco, CAJanuary 11-14, 2016Presentation: January 11, 2016 - 2:00PM Eastern

• Wells Fargo Specialty and Generic Drug SummitFebruary 22, 2016New York, NYPresentation time TBD

• RBC Healthcare ConferenceFebruary 23-24, 2016New York, NYPresentation day and time TBD

• Cowen & Co. Annual Health Care ConferenceMarch 7-9, 2016Boston, MAPresentation day and time TBD

Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as this information becomes available.

For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions Inc.Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com.

Follow us on twitter: @emergentbiosolu. 

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]

Media Contact:
Tracey Schmitt Lintott
Vice President, Global Public Affairs
and Corporate Responsibility
240-631-3394
[email protected]

Source: Emergent BioSolutions Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Genco Shipping & Trading Limited Responds to Diana Shipping Extending its Inadequate $24.80 Unsolicited Tender Offer
• KeyBanc Reiterates Overweight Rating on Worthington Steel Inc (WS)